Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
114.00    2.50 (2.24%)
Bid:
112.00
Ask:
116.00
Spread: 4.00 (3.571%)
Market Cap: £68.59m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Amendments to LTIP

21 Aug 2012 07:00

RNS Number : 3943K
Intercede Group PLC
21 August 2012
 

21 August 2012

Intercede Group plc

("Intercede" or "the Company"))

 

Changes to Long Term Incentive Plan (LTIP)

 

Intercede is pleased to announce that, following consultation with the Company's major shareholders, the Remuneration Committee has approved certain changes to the performance conditions attached to awards made under the Company's LTIP on 16 August 2011. The changes are a result of Richard Parris, the Company's Chairman & Chief Executive, communicating to the Remuneration Committee that he would not exercise options until the price per ordinary share exceeded 200p.

 

In considering this communication, the Remuneration Committee noted that Intercede's recently announced strategy of accelerated investment in technology development and the expansion of its US footprint and capabilities was not consistent with an EPS performance target under the LTIP. The Remuneration Committee consider, having taken appropriate advice, that the change in strategy represents an event under the terms of the LTIP that allows a change to performance targets to be made.

 

Consequently the Remuneration Committee has removed the three year EPS performance target from the LTIP awards made in August 2011 and replaced it with a share price target of 200p per ordinary share as well as extending the vesting period to seven years from the date of the original award. In order to exercise the option, an average share price of 200p per ordinary share must be achieved over 30 consecutive dealing days during the period between three years and seven years from the date of the original award.

 

In addition, participants have agreed to the insertion of a further performance condition. In the event of a recommended offer for the Company at any price below 125p per ordinary share, the option will only be exercisable over such number of shares that are equivalent in value to the difference between 56p (being the mid-market share price at the time of the original grant of 57p less the 1p exercise price) and the offer price. This also means that the option would not be exercisable at all at a recommended offer price of less than 57p. At any price above 125p, or in the event of an offer that is not recommended by the Board, the option vests in full.

 

All other terms and conditions of the LTIP remain unchanged.

 

Royston Hoggarth, the Chairman of the Remuneration Committee said: "Intercede is a global software company that needs to invest to increase its market penetration and long term valuation. The Remuneration Committee consider an overall share price target more appropriately aligns the interests of the beneficiaries of the LTIP and shareholders than a short or medium term EPS performance target. The willingness by Richard to communicate a share price target that is over three times higher than the price today, and the agreement by participants to the takeover condition, demonstrates their confidence and belief in the business."

 

 

 

 

 

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Tel. + 44 (0)20 7220 0500

Stuart Andrew/Rose Herbert, Corporate Finance

Joanna Weaving, Corporate Broking

Pelham Bell Pottinger

Tel. +44 (0)20 7861 3112

Archie Berens

 

About Intercede

Intercede® is a security software provider whose MyID® identity management platform enables global organisations and governments to create trusted digital identities for employees and citizens on secure devices such as smartcards, smartphones and tablets. MyID enables the protection of IP, assets, and digital content, delivering trusted digital identities as the cornerstone of cyber security strategies for government, defence, financial services and other industries.

The Company operates in global markets (including the US, Europe and Middle East) and works with large international partners including BT, Gemalto, HP, Microsoft, Oberthur, SafeNet, Symantec and Thales to deliver flexible digital identity solutions that are interoperable with other existing technologies and which are tailored to customer needs.

Corporations such as Boeing, Booz Allen Hamilton and Lockheed Martin,and governments including the USA, UK and Kuwait, trust Intercede's deep expertise to deliver effective solutions. The company's technology achievements reflect an investment of 300 plus man years of development, exemplary speed of deployment and adherence to international standards including FIPS 201, where MyID was the first electronic personalization product to obtain GSAapproval. This trust is reflected in Intercede's rate of repeat business with its customers, which typically runs at 70-80% of annual revenues.

Intercede has been developing ID management systems since 1992 and MyID is currently deployed by end customers located in 24 countries. The company is headquartered in the UK, listed on the London Stock Exchange AIM: IGP and ISO 9001 and TickIT certified.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMGZRDGLGZZM
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.